BTK and B-cell chronic lymphocytic leukemia: The BTK inhibitor used, Ibrutinib (Imbruvica®, previously PCI-32765), is a first-in-class irreversible inhibitor of BTK and is FDA approved for chronic lymphocytic leukemia [53].